Speaking at his party’s annual conference in Brighton, UK, Labour leader Jeremy Corbyn said he would legislate to create a state-run generic drugs firm, if elected.
Dubbed “Medicines For The Many,” the legislation would also permit compulsory licensing to obtain generic versions of branded products in certain cases, as well as provisions to force pharmaceutical firms to lower prices in return for research funding.
Controversy over drug pricing has been inflamed by a long-running standoff between Vertex Pharmaceuticals' (Nasdaq: VRTX) and the UK’s reimbursement agency, the NICE, over the price of Orkambi (lumacaftor/ivacaftor).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze